Eligibility for screening with low-dose CT in a real-world cohort of patients with lung cancer in Greece: A brief report

Maria Effrosyni Livanou, Nikolaos K. Syrigos, Austin Montgomery, Camille Moeckel, Emmanouil Panagiotou, Andriani Charpidou, Ioannis Mouratidis, Ilias Georgakopoulos-Soares, Ioannis A. Vathiotis

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: NELSON and NLST prompted the implementation of lung cancer screening programs in the United States followed by several European countries. This study aimed to assess the sensitivity of different screening criteria among patients with lung cancer in Greece and investigate reasons for ineligibility. Methods: We performed a retrospective analysis on patients with lung cancer referred to the largest referral center in Athens, Greece, between June 2014 and May 2023. The proportion of patients who would meet the updated USPSTF and NLST criteria was compared to the corresponding proportion of the Greek population over 15 years of age. Results: Out of 2434 patients with lung cancer, 77.4 % (N = 1883) would meet the updated USPSTF criteria, and 58.9 % (N = 1439) would meet the NLST criteria at diagnosis; the corresponding proportions for the Greek population over 15 years would be 13.8 % and 8.2 %, respectively. Ineligible patients were more likely to be female, former or never-smokers, have adenocarcinoma histology, and have driver mutations (p < 0.001). Conclusions: Although the updated USPSTF criteria demonstrated good sensitivity, a substantial proportion of patients with lung cancer would still not be eligible for screening. Future studies to shape a comprehensive screening strategy should focus on the incorporation of additional risk factors for lung cancer, including air pollution and individual genetic susceptibility.

Original languageEnglish (US)
Article number107424
JournalLung Cancer
Volume186
DOIs
StatePublished - Dec 2023

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this